Merck KGaA Moves 2d EGFR Agent Into Full Development; Erbitux On Track
Merck KGaA is moving the fully humanized epidermal growth factor receptor blocking antibody EMD-72000 into Phase II studies this year
You may also be interested in...
ImClone's oncologic agent Erbitux is "an active anticancer agent," Bristol-Myers Squibb and FDA Oncologic Drug Products Division Director Richard Pazdur, MD, agreed during a June 13 Energy & Commerce/Oversight Subcommittee hearing
Merck KGaA's European licensing application for cetuximab (ImClone's Erbitux) will include 330 colorectal cancer patients
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011